Waycross Partners’s Guardant Health GH Stock Holding History

Waycross Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,800	Closed	-$280K	–	81
2021 Q4	$280K	Buy	+2,800	New	+$290K	0.16%	85

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Waycross Partners's GH Position: Q1 2022 in Review

Waycross Partners sold out of Guardant Health (GH) in Q1 2022, closing a stake of 2,800 shares — an estimated $280K sold.

Waycross Partners first reported a position in GH in Q4 2021 and held it in 1 quarter. The position peaked at $280K in Q4 2021. 356 funds tracked by Wall St. Rank hold GH as of Q1 2022.

Waycross Partners reported no remaining Guardant Health position as of Q1 2022 after selling out during the quarter.
Waycross Partners sold 2,800 Guardant Health shares in Q1 2022, an estimated $280K.
Waycross Partners first reported a position in Guardant Health in Q4 2021 and held it in 1 quarter.
Waycross Partners's Guardant Health position peaked at $280K in Q4 2021.
356 funds tracked by Wall St. Rank held Guardant Health as of Q1 2022.

Based on Waycross Partners's 13F filing for Q1 2022, filed 29 Apr 2022.